Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/30938
Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study
Título : Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study |
Autor : Arroyo, Rafael Perez-Sempere, Angel ![](/image/ORCID.jpg) Ruiz-Beato, Elena Prefasi, Daniel ![](/image/ORCID.jpg) Carreño, Agata Roset, Montse ![](/image/ORCID.jpg) Maurino, Jorge |
Editor : BMJ |
Departamento: Departamentos de la UMH::Medicina Clínica |
Fecha de publicación: 2017-03 |
URI : https://hdl.handle.net/11000/30938 |
Resumen :
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS).
Design: A cross-sectional observational study.
Setting: The data reported were from 17 MS units throughout Spain.
Participants: Adult patients with relapsing-remitting MS.
Main outcome: A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration.
Results: Patients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT.
Conclusions: Patient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk-benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.
|
Palabras clave/Materias: conjoint analysis disease-modifying therapies patient preferences rating-based experiment |
Tipo documento : application/pdf |
Derechos de acceso: info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
DOI : https://doi.org/10.1136/bmjopen-2016-014433 |
Aparece en las colecciones: Artículos Medicina Clínica
|
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.